Status:
WITHDRAWN
Re-induction of a Systemic Immune Response in Metastatic or Locally Recurrent Lung Cancer
Lead Sponsor:
Maastricht Radiation Oncology
Conditions:
Lung Cancer Stage IV
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Patients with metastatic non-small cell lung cancer (NSCLC) who after an initial response to immunotherapy of chemo-immunotherapy show diffuse disease progression are treated with chemotherapy, with a...
Detailed Description
Metastatic non-small cell lung cancer (NSCLC) has always had a remarkably high mortality, with a 5-year overall survival (OS) rate of only 6%.However, immune checkpoint inhibitors (ICI) targeting the ...
Eligibility Criteria
Inclusion
- Stage IV NSCLC
- An initial partial or complete remission under immune therapy alone or concurrent immune therapy and chemotherapy
- Subsequently progressive disease according to RECIST 1.1 criteria
- Considered by the treating physician to be able to continue the same immune treatment as standard of care
- At least two different lesions should show progressive disease
- At least one progressing lesion should be eligible for radiation
Exclusion
- Patients with any grade 3 or higher toxicity from previous therapy
- Patients who are not eligible for continuation of the immune therapy according to standard practice
- Corticosteroids in a dose above 10 mg prednisone or equivalent per day. Corticoids used as supportive therapy for systemic or radiotherapy are allowed
Key Trial Info
Start Date :
December 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2026
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT06024941
Start Date
December 1 2024
End Date
December 1 2026
Last Update
September 19 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Maastricht Radiation Oncology (Maastro)
Maastricht, Netherlands, 6229 ET